Targeted Proteomic Quantitation of NRF2 Signaling and Predictive Biomarkers in HNSCC.

ABSTRACT: The NFE2L2 (NRF2) oncogene and transcription factor drives a gene expression program that promotes cancer progression, metabolic reprogramming, immune evasion, and chemoradiation resistance. Patient stratification by NRF2 activity may guide treatment decisions to improve outcome. Here, we developed a mass spectrometry-based targeted proteomics assay based on internal standard-triggered parallel reaction monitoring to quantify 69 NRF2 pathway components and targets, as well as 21 proteins of broad clinical significance in head and neck squamous cell carcinoma (HNSCC). We improved an existing internal standard-triggered parallel reaction monitoring acquisition algorithm, called SureQuant, to increase throughput, sensitivity, and precision. Testing the optimized platform on 27 lung and upper

SUBMITTER: Wamsley NT 

PROVIDER: S-EPMC10587640 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature